Valuation: Nuvalent, Inc.

Capitalization 8.08B 6.88B 6.37B 6B 11.17B 751B 11.4B 74.71B 29.23B 361B 30.31B 29.67B 1,285B P/E ratio 2026 *
-18.1x
P/E ratio 2027 * -23.4x
Enterprise value 7.21B 6.15B 5.69B 5.36B 9.98B 671B 10.18B 66.73B 26.11B 322B 27.07B 26.5B 1,148B EV / Sales 2026 *
522x
EV / Sales 2027 * 38.7x
Free-Float
85.54%
Yield 2026 *
-
Yield 2027 * -
1 day-1.77%
1 week-2.55%
Current month+0.28%
1 month+2.69%
3 months-2.20%
6 months+16.62%
Current year+2.14%
1 week 99.78
Extreme 99.785
106.39
1 month 93.91
Extreme 93.91
106.9
Current year 93.91
Extreme 93.91
113.02
1 year 63.56
Extreme 63.555
113.02
3 years 25.31
Extreme 25.31
113.51
5 years 7.09
Extreme 7.09
113.51
10 years 7.09
Extreme 7.09
113.51
Manager TitleAgeSince
Chief Executive Officer 50 2016-12-31
Director of Finance/CFO 42 2020-12-31
Chief Tech/Sci/R&D Officer - 2024-07-10
Director TitleAgeSince
Director/Board Member 50 2020-01-31
Chairman 47 2017-01-31
Director/Board Member 62 2020-12-31
Change 5d. change 1-year change 3-years change Capi.($)
-1.77%-2.55%+54.99%+282.79% 8.08B
+0.80%+5.38%+33.62%+97.05% 49.79B
+0.13%+6.34%+104.09%+26.89% 46.97B
-3.00%-4.69%+125.77%+817.66% 33.42B
+3.83%+4.74%-1.06%-24.41% 24.15B
+1.01%+2.63%+80.04%-28.20% 18.97B
-0.69%+1.79%+46.12%-32.55% 17.25B
+1.99%-1.64%+68.13%+202.08% 16.25B
+1.86%+1.50%-15.36%+1,129.38% 15.25B
+1.61%-2.09%+63.25% - 14.68B
Average +0.58%+1.14%+55.96%+274.52% 24.48B
Weighted average by Cap. +0.47%+2.24%+62.50%+236.94%

Financials

2026 *2027 *
Net sales 13.81M 11.77M 10.89M 10.25M 19.1M 1.28B 19.49M 128M 49.99M 617M 51.84M 50.74M 2.2B 183M 156M 144M 136M 253M 17.02B 258M 1.69B 662M 8.17B 687M 672M 29.13B
Net income -444M -378M -350M -330M -614M -41.29B -626M -4.11B -1.61B -19.83B -1.67B -1.63B -70.64B -350M -298M -276M -260M -484M -32.56B -494M -3.24B -1.27B -15.63B -1.31B -1.29B -55.7B
Net Debt -863M -735M -680M -640M -1.19B -80.22B -1.22B -7.98B -3.12B -38.52B -3.24B -3.17B -137B -1B -852M -789M -743M -1.38B -93.06B -1.41B -9.25B -3.62B -44.69B -3.76B -3.68B -159B
Logo Nuvalent, Inc.
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases and drive more durable responses. It is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, NVL-520, is being developed for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, NVL-655, is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC. LC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor.
Employees
228
Date Price Change Volume
26-04-10 102.74 $ -1.77% 412,855
26-04-09 104.59 $ -0.43% 396,736
26-04-08 105.04 $ +2.73% 370,481
26-04-07 102.25 $ -1.41% 628,261
26-04-06 103.71 $ -1.63% 766,350
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
102.74USD
Average target price
142.39USD
Spread / Average Target
+38.59%

Quarterly revenue - Rate of surprise